FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*					2. Issuer Name and Ticker or Trading Symbol Cue Biopharma, Inc. [CUE]						5. R (Che	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
MCKNIGHT STEVEN L									-			V Directo	r	10% O	wner	
(Last) (First) (Middle)					3. Date of Earliest Transaction (Month/Day/Year) 01/06/2020							Officer below)	(give title	Other (below)	specify	
21 ERIE STREET																
					4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Individual or Joint/Group Filing (Check Applicable Line)				
(Street)												,	led by One Re	porting Perso	n	
CAMBRIDGE MA 02139											Form filed by More than One Reporting					
(City)	(S	state)	(Zip)									1 013011				
		Tal	ole I - Non-	Derivati	ve Se	curities	Ac	quired, Di	sposed o	f, or Ber	neficiall	y Owned				
1. Title of Security (Instr. 3) 2. Transac Date (Month/Date)					Year)	2A. Deemed Execution Date, if any (Month/Day/Year)		Code (Instr. 5)			5. Amour Securitie Beneficia Owned F	s Fo ally (D) ollowing (I)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership		
							Code V	Amount	(A) or (D)	Price	Reported Transact (Instr. 3 a	ion(s)		(Instr. 4)		
			Table II - D	erivative	Sec	urities A	Acqu	uired, Disp	osed of,	or Bene	ficially	Owned	·			
			(е	.g., puis	, can	S, Warra	สกเร	, options,	converu	ne secu	rilles)					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security		3A. Deemed Execution Dat if any (Month/Day/Ye	Code	action (Instr.			6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)			
Stock Option (right to buy)	\$16.31	01/02/2020		A		8,000 ⁽¹⁾		01/02/2021	01/02/2030	Common Stock	8,000	\$0.00	8,000	D		

Explanation of Responses:

1. Represents a stock option award granted on January 2, 2020 pursuant to the Issuer's Non-Employee Director Compensation Policy.

Remarks:

/s/ Steven McKnight by Mark

01/06/2020

<u>Busch</u>, <u>attorney-in-fact</u>** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.